These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 9533471

  • 1. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S, Tebbs SE, Elliott TS.
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [Abstract] [Full Text] [Related]

  • 2. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE.
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [Abstract] [Full Text] [Related]

  • 3. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    Fraise AP, Andrews J, Wise R.
    J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
    Schwalbe RS, McIntosh AC, Qaiyumi S, Johnson JA, Johnson RJ, Furness KM, Holloway WJ, Steele-Moore L.
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
    [Abstract] [Full Text] [Related]

  • 5. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D, Brown DF, Soussy CJ.
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [Abstract] [Full Text] [Related]

  • 6. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
    Kirk M, Hill RL, Casewell MW, Beighton D.
    Adv Exp Med Biol; 1997 Aug; 418():483-5. PubMed ID: 9331699
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
    García-Garrote F, Cercenado E, Alcalá L, Bouza E.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2452-5. PubMed ID: 9736584
    [Abstract] [Full Text] [Related]

  • 9. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC.
    Drugs; 1997 Sep; 54 Suppl 6():11-20. PubMed ID: 9474477
    [Abstract] [Full Text] [Related]

  • 10. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A, Korzeniewski K, Nitsch-Osuch A, Rybicki Z, Prokop E.
    Adv Exp Med Biol; 2013 Sep; 788():125-32. PubMed ID: 23835969
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Cockerill FR, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Baltch AL, Smith RP, Ritz WJ, Bopp LH.
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro activity of teicoplanin against gram-positive cocci.
    Allouch P, Pina P, Chaplain C, Delarbre JM, Geffroy F, Grasmick CP, Marcolin M, Morel A, Pangon B, Rio Y, Sédaillan A.
    Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against gram-positive cocci.
    Ravizzola G, Pirali F, Foresti I, Turano A.
    Drugs Exp Clin Res; 1987 Oct; 13(4):225-9. PubMed ID: 2957187
    [Abstract] [Full Text] [Related]

  • 20. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
    Zeckel ML, Preston DA, Allen BS.
    Antimicrob Agents Chemother; 2000 May; 44(5):1370-4. PubMed ID: 10770782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.